Oluwatomisono Ikpomwosa Akinrimisi

Mr. Oluwatomisono Ikpomwosa Akinrimisi


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
OAOluwatomisono Ikpomwosa Akinrimisi
Oluwatomisono Ikpomwosa Akinrimisi
KMKim Maasen
Kim Maasen
JSJean Scheijen
Jean Scheijen
INIna Nemet
Ina Nemet
MNmax Nieuwdorp
max Nieuwdorp
NHNordin Hanssen
Nordin Hanssen
Methylglyoxal (MGO) is a highly reactive dicarbonyl associated with oxidative stress, inflammation, and chronic diseases, particularly diabetic vascular complications and atherosclerosis through the formation of advanced glycation end products (AGEs). In the setting of human/host diseases, the formation of MGO has mainly been considered as the byproduct of glycolysis. Gut microbes play an important role in the development of cardiometabolic diseases. Here, we discuss a possibility that gut microbes can modulate the MGO pool within the host through (i) the alternation of the host metabolism, and (ii) direct MGO synthesis and/or detoxification by human commensal microorganisms. We also explore how dietary MGO impacts the composition of the gut microbiota and their potential role in modulating host health. This paradigm is highly innovative, with the current literature providing observations supporting this concept. Targeting the gut microbiome is emerging as an approach for treating cardiometabolic diseases through dietary, pre-, pro-, and postbiotic interventions, faecal microbiota transplantations, and the use of small molecule inhibitors of microbial enzymes. This can be a novel strategy to reduce MGO stress in the setting of cardiometabolic diseases and lowering the burden of diabetic complications and cardiovascular disease.

29 July 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
OAOluwatomisono Ikpomwosa Akinrimisi
Oluwatomisono Ikpomwosa Akinrimisi
MKMijra Koning
Mijra Koning
JSJean Scheijen
Jean Scheijen
AMAbraham S. Meijnikman
Abraham S. Meijnikman
DSDaniko P. Sindhunata
Daniko P. Sindhunata
NHNordin Hanssen
Nordin Hanssen
Introduction: Methylglyoxal (MGO) is a very reactive compound that modifies proteins, forming advanced glycation end products (AGEs) and activating inflammatory pathways. Elevated MGO levels have been linked to various diseases, including type 2 diabetes and atherosclerosis. However, the role of MGO and other glycating agents in the progression of liver fibrosis in the setting of metabolic dysfunction associated steatotic liver disease (MASLD) is poorly understood. Methods: This study explores the relationship between plasma MGO levels and related dicarbonyls (glyoxal (GO) and 3‐deoxyglucosone (3‐DG)), which are measured using ultra‐high‐performance liquid chromatography tandem mass spectrometry (UPLC‐MS/MS), and liver fibrosis assessed via histological liver biopsy scoring and the Fibrosis‐4 (FIB‐4) Index. The study population comprised 264 severely obese individuals due to undergo bariatric surgery, a subset from the BARIA cohort (22% type 2 diabetes; 77% females; median age 47 (IQR: 39–54 years); BMI 39 (IQR: 36–41 kg/m 2 )). Results: MGO levels were significantly higher in individuals with type 2 diabetes compared with individuals without type 2 diabetes, with a median of 288 nmol/L (257–334 nmol/L) and 238 (212–279 nmol/L) respectively. MGO levels were higher in males compared with females, with a median of 267 (236–301 nmol/L) and 245 (214–288 nmol/L) respectively. Similar results were found for GO and 3DG. Higher plasma MGO, GO and 3DG levels were significantly associated with the FIB‐4 Index (MGO, rho = 0.21, p < 0.01), (GO, rho = 0.29, p < 0.01), (3DG, rho = 0.25, p < 0.05). Using linear regression models, the association between MGO and the FIB‐4 Index remained significant after adjustment for age (years), sex, BMI, sub‐cohort, smoking status, alcohol consumption, hypertension, HOMA‐IR, HbA1c and fasting glucose levels. Using ordinal logistic regression models, MGO and GO were also associated with liver fibrosis scoring from biopsy before and after adjustment for confounders (Age (years), sex, BMI, sub‐cohort, smoking status, alcohol consumption, hypertension, HOMA‐IR, HbA1c and fasting glucose levels). Notably, the relationships remained significant in individuals without type 2 diabetes and after adjusting for HbA1c and fasting glucose levels. No significant associations were observed between MGO, GO, or 3DG and steatosis or inflammation histology scores after adjustment for confounders. Conclusion: This study shows the potential role of dicarbonyl stress, particularly MGO, in liver fibrosis among obese individuals, highlighting its significance as an independent contributor to liver damage and a potential therapeutic target.